Myovant Sciences Stock News

Myovant Sciences (MYOV) sees total revenues to be in the range of $54 to $55M for the quarter ended Dec.31 compared to $1.4M in year ago quarter.Net product revenue is estimated to be…

BASEL, Switzerland, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced preliminary financial res

BASEL, Switzerland, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, Chief E

BASEL, Switzerland, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, Chief Exe

Due to the combination of a market downturn and other issues, Myovant shares depreciated substantially. Nevertheless, there are powerful fundamental advancements that signal much more upsides going in

Equities analysts forecast that Myovant Sciences Ltd. (NYSE:MYOV) will post sales of $56.34 million for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Myovant Sciences earnings. The lowest sales estimate is $53.28 million and the highest is $58.40 million. Myovant Sciences posted sales of $1.38 million during the same []

Summit Therapeutics (NASDAQ:SMMT) and Myovant Sciences (NYSE:MYOV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. Profitability This table compares Summit Therapeutics and Myovant Sciences net margins, return on equity and []

Myovant Sciences Ltd. (NYSE:MYOV)s share price reached a new 52-week low during trading on Tuesday . The stock traded as low as $13.91 and last traded at $15.09, with a volume of 1989213 shares changing hands. The stock had previously closed at $14.66. Several equities research analysts have commented on the company. SVB Leerink dropped []

Myovant Sciences Ltd. (NYSE:MYOV) insider Ferreira Juan Camilo Arjona sold 1,978 shares of the businesss stock in a transaction dated Monday, November 29th. The shares were sold at an average price of $19.30, for a total value of $38,175.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is []

Myovant Sciences Ltd. (NYSE:MYOV) shares hit a new 52-week low on Wednesday following insider selling activity. The company traded as low as $16.50 and last traded at $16.51, with a volume of 1372 shares changing hands. The stock had previously closed at $16.81. Specifically, major shareholder Chemical Co. Ltd. Sumitomo bought 89,864 shares of the []

Myovant Sciences Ltd (MYOV) shares closed today at 0.7% above its 52 week low of $16.69, giving the company a market cap of $1B. The stock is currently down 32.4% year-to-date, down 20.7% over the past 12 months, and up 45.1% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 0.6%. Trading Activity Trading volume this week was 29.4% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 0.6% The company's stock price performance over the past 12 months beats the peer average by -26.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Myovant Sciences Ltd. (NYSE:MYOV) shares fell 9.1% during mid-day trading on Tuesday . The company traded as low as $16.96 and last traded at $16.96. 26,840 shares changed hands during trading, a decline of 96% from the average session volume of 752,421 shares. The stock had previously closed at $18.66. A number of brokerages have […]

Wall Street brokerages predict that Myovant Sciences Ltd. (NYSE:MYOV) will announce sales of $56.34 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Myovant Sciences earnings, with estimates ranging from $53.28 million to $58.40 million. Myovant Sciences posted sales of $1.38 million in the same quarter last year, which []

During the last session, Myovant Sciences Ltd. (NYSE:MYOV)s traded shares were 0.69 million, with the beta value of the company hitting 2.72. At the end of the trading day, the stocks price was $19.93, reflecting an intraday gain of 2.21% or $0.43. The 52-week high for the MYOV share is $30.90, that puts it down How Myovant Sciences Ltd. (NYSE: MYOV) Could Be A Loss Maker Since It Is Down -27.84% YTD? Read More »